Literature DB >> 11226520

Co-biomodulation with arsenic trioxide in multiple myeloma.

R E Gallagher1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226520     DOI: 10.1016/s0145-2126(00)00144-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  2 in total

1.  Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.

Authors:  Rony M Abou-Jawde; Janice Reed; Megan Kelly; Esteban Walker; Steven Andresen; Rachid Baz; Mary Ann Karam; Mohamad Hussein
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.

Authors:  Alejo A Morales; Delia Gutman; Pedro J Cejas; Kelvin P Lee; Lawrence H Boise
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.